SCHEMBL17015691

SCHEMBL17015691

O=C(c1ccccc1)c1ccc(-n2c3ccccc3c3ccc4c(ccn4-c4ccc(-c5ccccc5)cc4)c32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HDAC4 P56524 1/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PTPN1 P18031 1/20 0.37
RORC P51449 5/20 0.36
CNR2 P34972 2/20 0.36
CYP19A1 P11511 2/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4E B2RXH2 2/20 0.35
CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015222 0.94 L3MBTL1 (0.41) CA12CA1CA2CA9LMNA
SCHEMBL17016174 0.94 L3MBTL1 (0.41) CA12CA1CA2CA9LMNA
SCHEMBL17015695 0.92 CYP19A1 (0.38) CA12CA1CA2CA9HDAC4
SCHEMBL17015771 0.92 CNR2 (0.36) CA12CA1CA2CA9HDAC4
SCHEMBL17015698 0.91 MAPK1 (0.36) HDAC4LMNAMAPTRAB9AMEN1
SCHEMBL16613787 0.89 L3MBTL1 (0.43) HDAC4MAPTMEN1KMT2AKDM4E
SCHEMBL15632083 0.89 L3MBTL1 (0.43) HDAC4MAPTMEN1KMT2AKDM4E
SCHEMBL16357351 0.88 L3MBTL1 (0.46) HDAC4MAPTMEN1KMT2AKDM4E
SCHEMBL16613776 0.88 L3MBTL1 (0.46) HDAC4MAPTMEN1KMT2AKDM4E
SCHEMBL17015700 0.88 L3MBTL1 (0.46) HDAC4MAPTMEN1KMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 CA12 4613/4885CA1 4050/4885CA2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.